SEB Asset Management AB Acquires New Stake in ANI Pharmaceuticals, Inc. $ANIP

SEB Asset Management AB bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 38,114 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,931,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Swiss National Bank boosted its stake in ANI Pharmaceuticals by 1.1% during the 1st quarter. Swiss National Bank now owns 35,500 shares of the specialty pharmaceutical company’s stock valued at $2,730,000 after purchasing an additional 400 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of ANI Pharmaceuticals by 52.0% in the 1st quarter. Bessemer Group Inc. now owns 57,909 shares of the specialty pharmaceutical company’s stock worth $4,454,000 after buying an additional 19,800 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of ANI Pharmaceuticals by 11.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,257 shares of the specialty pharmaceutical company’s stock worth $779,000 after buying an additional 1,062 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $1,453,000. Finally, Principal Financial Group Inc. boosted its stake in ANI Pharmaceuticals by 19.1% during the first quarter. Principal Financial Group Inc. now owns 129,148 shares of the specialty pharmaceutical company’s stock valued at $9,931,000 after buying an additional 20,679 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 85,179 shares of company stock worth $6,722,596 in the last three months. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

ANIP opened at $78.53 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The firm has a market cap of $1.79 billion, a PE ratio of 19.88 and a beta of 0.43. The business has a fifty day simple moving average of $81.26 and a 200-day simple moving average of $79.48. ANI Pharmaceuticals, Inc. has a fifty-two week low of $62.60 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the previous year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ANIP. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Finally, Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 16th. They issued a “hold” rating and a $91.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.00.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.